{
    "clinical_study": {
        "@rank": "3244", 
        "arm_group": {
            "arm_group_label": "Ketorolac Tromethamine", 
            "arm_group_type": "Other", 
            "description": "Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days."
        }, 
        "brief_summary": {
            "textblock": "Intranasal Ketorolac tromethamine has a potential role as a short term pain management tool\n      for Interstitial Cystitis without the risk and undesirable effects of narcotics."
        }, 
        "brief_title": "Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Interstitial Cystitis", 
        "condition_browse": {
            "mesh_term": [
                "Cystitis", 
                "Cystitis, Interstitial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Female Subject must be between the age eighteen (18) years and sixty four (64)\n\n          2. Subject must weigh 110lbs (50kg) or greater\n\n          3. Willing and able to provide an informed consent\n\n          4. Diagnosed with Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)\n\n          5. Symptoms of IC/PBS that are moderate to severe (intermittent or chronic) for \u2265 three\n             (3) months\n\n          6. A cystoscopic examination under anesthesia with hydro-distention and photo\n             documentation will have been performed at time of diagnosis with IC. Bladder biopsies\n             will have been performed only if carcinoma is suspected. (see exclusion # 5.2.25 -\n             hydrodistention must be performed greater than  four (4) weeks prior to baseline\n             visit) Note: at investigator discretion subject may included with only operative\n             report\n\n          7. At screening  subject must have a score \u2265 four (4) out of ten (10) On Visual Analogue\n             Pain Scale  (VAS Pain Scale)\n\n          8. Subject must  have a score on the O'Leary/Sant scale  of at least a five (5) on the\n             symptom index at screening\n\n          9. Voids greater than eight (8) in a twenty four (24) hour period\n\n         10. Nocturia of at least one (1) time during sleeping period\n\n         11. Subject of child-bearing potential must test negative for pregnancy prior to\n             treatment or provide documentation for having undergone the following:  hysterectomy\n             or tubal ligation.  Subjects who are physiologically capable of becoming pregnant\n             must voluntarily sign a pregnancy waiver included within the informed consent and\n             agree not to become pregnant for the duration of the study and for thirty (30) days\n             following the completion of study.  If a subject becomes pregnant during the course\n             of this study, the subject will inform the Principal Investigator within one (1)\n             working day of learning of the pregnancy\n\n        Exclusion Criteria:\n\n          1. Current treatment with or known allergy or sensitivity to all forms of ketorolac\n             tromethamine, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs) or\n             Ethylenediaminetetraacetic acid (EDTA) NOTE: if at time of signing consent a subject\n             is receiving a non-steroidal inflammatory drug they may washout for seven days prior\n             to completing the screening visit\n\n          2. Subject is currently receiving or having had prior IC/PBS focused therapy on less\n             than three (3) months stable doses.  i.e. oral Pentosan Polysulfate(PPS) (Elmiron\u00ae),\n             Amitriptyline (Elavil\u00ae), oxychlorosene (Clorpactin\u00ae), dimethyl sulfoxide (RIMSO 50\u2122),\n             heparin  or antihistamine NOTE:   Antihistamine is allowable as added treatment\n             during course of study if for  treatment of diagnosed nasal/seasonal/environmental\n             allergy (i.e treatment other than IC) , If a subject is receiving intravesical\n             instillations of any kind at least a two day washout must be adhered to before\n             screening is performed.  The subject must abstain from any intravesical instillation\n             during the study.\n\n          3. Current use of TENS (Transcutaneous Electrical Nerve Stimulation) or Interstim unit\n\n          4. Clinically significant urinary tract infection (UTI) NOTE: dipstick urinalysis is\n             done at screening urine culture will be performed if indicated by results of dipstick\n             urinalysis at screening\n\n          5. As needed Use of narcotics/opiate within one (1) week prior  to the screening visit\n             and entire study participation by self-reporting (Note: once subject has qualified\n             they will be given the option of rescue medication for pain not relieved by the study\n             medication)\n\n          6. Use of illegal drugs by self-reporting\n\n          7. History of drug or alcohol abuse within five (5) years of screening visit\n\n          8. History of suicide attempt or suicidal thoughts by self-reporting within five (5)\n             years of screening visit\n\n          9. Any active co-morbid pelvic diagnosis (i.e. endometriosis, Irritable Bowel Syndrome,\n             etc.) for which the subject is unable to distinguish between IC/PBS pain and pain\n             from any other condition as determined by the investigator\n\n         10. A  diagnosis of a severe neuro-psychiatric disease\n\n         11. Subject demonstrates an absence of nocturia\n\n         12. Subject's frequency of urination is equal to or less than eight (8) times in a twenty\n             four (24) hour period.\n\n         13. Subject's symptoms relieved by antimicrobials, urinary antiseptics, anticholinergics,\n             or antispasmodics.\n\n         14. Subject has recurrent bladder or lower urethral calculi (recurrent is defined as > to\n             3 times in a 12 month period)\n\n         15. Subject has active genital herpes with a (3) three  month period of the screening\n             visit\n\n         16. Subject has uterine, cervical, vaginal, or urethral cancer\n\n         17. Subject has been administered cyclophosphamide or any agent that causes chemical\n             cystitis\n\n         18. Subject has tubercular cystitis\n\n         19. Subject has radiation cystitis\n\n         20. Subject has benign or malignant bladder tumor\n\n         21. Subject has a positive pathologic vaginal culture within three (3) months of the\n             screening visit\n\n         22. Subject has evidence of vesicle ureteral reflux or urethral diverticula\n\n         23. Subject has neurogenic bladder dysfunction\n\n         24. Subject has a prior urinary diversion\n\n         25. Subject who is currently receiving investigational  drug(s) or participated in a\n             clinical trial involving investigational drug(s) within thirty (30) day of the\n             screening visit\n\n         26. Subject who is pregnant or lactating\n\n         27. Subject with history of hydro-distention within four (4) weeks of baseline visit\n\n         28. Subject with history of clinically significant cardiovascular disease such as:\n             (chronic stable angina being currently treated with long acting nitrates, chronic\n             stable angina require treatment with short acting nitrates with 90 days of visit 1,\n             angina occurring during sexual intercourse in the last six months, unstable angina\n             within six months of visit 1\n\n         29. Resting, sitting blood pressure (BP) > 160mm Hg in systolic pressure or > 100mm Hg is\n             diastolic pressure at screening.  If a patient is found to have untreated significant\n             hypertension at screening and antihypertensive treatment is initiated, assessment for\n             study eligibility should be deferred until BP and antihypertensive medication have\n             been stable for at least one month.  For patients with previously diagnosed\n             hypertension, antihypertensive medications must be stable for at least one month\n             prior to screening.\n\n         30. Subject over sixty four (64) years of age\n\n         31. Subject who weighs less than 110lbs (50kg)\n\n         32. Subject with history of any clinically significant blood chemistry, renal function or\n             liver abnormality defined as + two (2X) normal values\n\n         33. Subject who has history of a bleeding problem or low platelet count\n\n         34. Known or suspected cerebrovascular bleeding, hemorrhagic diathesis or incomplete\n             hemostasis, and those at high risk of bleeding, have history of a bleeding problem or\n             low platelet count or coagulation disorder or are on therapy that affects homeostasis\n\n         35. Active peptic ulcer disease, recent GI bleeding or perforation, or a history of\n             peptic ulcers or GI bleeding\n\n         36. History of asthma, urticaria or other allergic-type reaction after taking aspirin or\n             other  non- steroidal inflammatory drugs (NASIDs)\n\n         37. Subject who has history of swelling of face, mouth, tongue, lips, gums, neck, or\n             throat (angioedema) or with cardiac decompensation or similar conditions\n\n         38. Major surgery scheduled within 3 weeks or screening and for entire participation of\n             study\n\n         39. Current exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal\n             necrolysis\n\n         40. Any condition in the opinion of the investigator that makes the subject unsuitable\n             for study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000401", 
            "org_study_id": "0703-2012-SPRIX"
        }, 
        "intervention": {
            "arm_group_label": "Ketorolac Tromethamine", 
            "intervention_name": "Ketorolac Tromethamine", 
            "intervention_type": "Drug", 
            "other_name": "SPRIX"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ketorolac Tromethamine", 
                "Ketorolac"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendora", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91741"
                }, 
                "name": "Citrus Valley Medical Research, Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain", 
        "overall_official": {
            "affiliation": "Citrus Valley Medical Research, Inc.", 
            "last_name": "Edward L Davis, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pain Scores on the Visual Analog Scale", 
            "safety_issue": "No", 
            "time_frame": "5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "5 days"
        }, 
        "source": "Citrus Valley Medical Research, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Citrus Valley Medical Research, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}